Optimind Pharma Announces Adoption of Semi-Annual Reporting

Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") announces that it has elected to voluntarily adopt semi-annual financial reporting and rely on the exemptions in Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933").

Introduced by the Canadian Securities Administrators (CSA), the pilot program under CBO 51-933 allows eligible venture issuers to voluntarily transition from quarterly to semi-annual financial reporting. By adopting semi-annual reporting, the Company intends to reduce the administrative and financial burdens associated with frequent interim reporting, allowing management to allocate additional time and resources toward advancing the Company's core business objectives.

The Company has a February 28 fiscal year end. Pursuant to the exemptions in CBO 51-933, the Company will no longer be required to file interim financial reports and related management's discussion and analysis ("MD&A") for its first and third quarters.

The first interim period for which the Company will rely on the exemptions in CBO 51-933 and not file quarterly financial disclosure is the three-month period ended May 31, 2026 (the "2026 Q1 Interim Period"). If the Company were not relying on the exemptions in CBO 51-933, the financial disclosure for the 2026 Q1 Interim Period would otherwise be required to be filed by July 30, 2026 under applicable securities laws.

The Company's next scheduled financial report will be for the six-month interim period ending August 31, 2026, in accordance with the timelines prescribed under applicable securities laws. The Company intends to continue reporting on a semi-annual basis, subject to the continued availability of CBO 51-933 and the Company remaining eligible thereunder.

The Company will continue to file its audited annual financial statements and related MD&A, as well as its six-month interim financial statements and related MD&A, in accordance with applicable securities laws. Furthermore, the Company remains subject to, and will continue to comply with, all timely continuous disclosure obligations, including the required reporting of material changes.

This news release is being filed pursuant to Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers.

About Optimind Pharma Corp. The Company is a reporting issuer in the Canadian jurisdictions of Alberta, British Columbia and Ontario and is listed on the Canadian Securities Exchange under the symbol "OMND".